Analysts forecast that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) will post earnings of ($0.27) per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from ($0.31) to ($0.22). Oramed Pharmaceuticals posted earnings per share of ($0.15) during the same quarter last year, which would indicate a negative year over year growth rate of 80%. The business is scheduled to issue its next earnings report on Thursday, July 5th.
According to Zacks, analysts expect that Oramed Pharmaceuticals will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.83). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.35) per share, with EPS estimates ranging from ($1.52) to ($1.13). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Oramed Pharmaceuticals.
Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings results on Sunday, April 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.11. The business had revenue of $0.60 million during the quarter, compared to the consensus estimate of $0.62 million. Oramed Pharmaceuticals had a negative return on equity of 49.15% and a negative net margin of 165.00%.
A hedge fund recently bought a new stake in Oramed Pharmaceuticals stock. Millennium Management LLC purchased a new position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,849 shares of the biotechnology company’s stock, valued at approximately $143,000. Millennium Management LLC owned 0.11% of Oramed Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 1.91% of the company’s stock.
Shares of Oramed Pharmaceuticals traded down $0.21, reaching $7.00, during trading hours on Tuesday, MarketBeat Ratings reports. 37,967 shares of the stock traded hands, compared to its average volume of 26,419. Oramed Pharmaceuticals has a one year low of $6.15 and a one year high of $11.34.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.